TG4050: Updated randomized Phase I data to be presented in Rapid Oral Presentation at ASCO 2025
Dr. Simone Steiner appointed Chief Technical Officer (CTO)
Business funded until the end of April 2026
Strasbourg, France, April 24, 2025, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today provides a business update, including its financial position as of March 31, 2025.
Key events and upcoming milestones
Over the first quarter of 2025, all of Transgene’s preclinical and clinical assets progressed in line with expectations.
.../...
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer